S&P 500   5,076.55 (+0.13%)
DOW   38,876.87 (-0.19%)
QQQ   437.45 (+0.50%)
AAPL   180.23 (-0.66%)
MSFT   408.04 (+0.08%)
META   485.86 (+0.38%)
GOOGL   136.83 (+0.33%)
AMZN   174.75 (+0.92%)
TSLA   200.30 (-0.86%)
NVDA   791.73 (+1.94%)
NIO   5.64 (+3.87%)
AMD   187.86 (+6.41%)
BABA   74.17 (-0.56%)
T   16.99 (+0.18%)
F   12.38 (+0.65%)
MU   89.48 (-0.26%)
CGC   3.33 (-0.89%)
GE   155.77 (+0.10%)
DIS   111.28 (+0.43%)
AMC   4.41 (-11.62%)
PFE   26.74 (-1.11%)
PYPL   60.10 (-0.25%)
XOM   104.72 (+0.38%)
S&P 500   5,076.55 (+0.13%)
DOW   38,876.87 (-0.19%)
QQQ   437.45 (+0.50%)
AAPL   180.23 (-0.66%)
MSFT   408.04 (+0.08%)
META   485.86 (+0.38%)
GOOGL   136.83 (+0.33%)
AMZN   174.75 (+0.92%)
TSLA   200.30 (-0.86%)
NVDA   791.73 (+1.94%)
NIO   5.64 (+3.87%)
AMD   187.86 (+6.41%)
BABA   74.17 (-0.56%)
T   16.99 (+0.18%)
F   12.38 (+0.65%)
MU   89.48 (-0.26%)
CGC   3.33 (-0.89%)
GE   155.77 (+0.10%)
DIS   111.28 (+0.43%)
AMC   4.41 (-11.62%)
PFE   26.74 (-1.11%)
PYPL   60.10 (-0.25%)
XOM   104.72 (+0.38%)
S&P 500   5,076.55 (+0.13%)
DOW   38,876.87 (-0.19%)
QQQ   437.45 (+0.50%)
AAPL   180.23 (-0.66%)
MSFT   408.04 (+0.08%)
META   485.86 (+0.38%)
GOOGL   136.83 (+0.33%)
AMZN   174.75 (+0.92%)
TSLA   200.30 (-0.86%)
NVDA   791.73 (+1.94%)
NIO   5.64 (+3.87%)
AMD   187.86 (+6.41%)
BABA   74.17 (-0.56%)
T   16.99 (+0.18%)
F   12.38 (+0.65%)
MU   89.48 (-0.26%)
CGC   3.33 (-0.89%)
GE   155.77 (+0.10%)
DIS   111.28 (+0.43%)
AMC   4.41 (-11.62%)
PFE   26.74 (-1.11%)
PYPL   60.10 (-0.25%)
XOM   104.72 (+0.38%)
S&P 500   5,076.55 (+0.13%)
DOW   38,876.87 (-0.19%)
QQQ   437.45 (+0.50%)
AAPL   180.23 (-0.66%)
MSFT   408.04 (+0.08%)
META   485.86 (+0.38%)
GOOGL   136.83 (+0.33%)
AMZN   174.75 (+0.92%)
TSLA   200.30 (-0.86%)
NVDA   791.73 (+1.94%)
NIO   5.64 (+3.87%)
AMD   187.86 (+6.41%)
BABA   74.17 (-0.56%)
T   16.99 (+0.18%)
F   12.38 (+0.65%)
MU   89.48 (-0.26%)
CGC   3.33 (-0.89%)
GE   155.77 (+0.10%)
DIS   111.28 (+0.43%)
AMC   4.41 (-11.62%)
PFE   26.74 (-1.11%)
PYPL   60.10 (-0.25%)
XOM   104.72 (+0.38%)

10 Best Small Cap Stocks to Buy Now

Let's talk about small cap stocks. It's common knowledge that tilting your stock portfolio toward smaller-capitalization companies will generally outperform the S&P 500 over a long enough period of time. Companies that have a market value between $300 million and $2 billion tend to outperform their large cap counterparts simply because they have a lot more room to grow and haven't saturated their markets yet.

While small cap stocks provide some of the best growth opportunities in public markets, they are also much more volatile than their large cap counterparts. Many large cap companies that are name brands among retail investors (Apple, Tesla, etc.) move in unison with the total direction of the market.

It's a different situation with small cap stocks. There are clear winners and losers over the course of the year. Price performance is much more dependent on a small cap's stock performance (earnings per share) and how much interest there is in the company among retail investors. If a small cap stock has strong earnings and gains a following on sites like Seeking Alpha and MarketBeat, they can see their stock price double or triple over the course of a year. That typically doesn't happen with their large cap counterparts.

How do you find the winners though? Sure, you can buy a small cap index ETF and get average returns and you'll do fine over the course of time. But, what if there was a way to identify the best small caps to buy now without having a crystal ball? It's impossible to say with certainty what the best performing small cap stocks will be next year, but we polled the most-accurate and best-performing research analysts on Wall Street to see what they have to say.

Wall Street analysts publish more than 48,000 research notes on small cap companies each year. We've compiled a list of the 10 stocks that they are consistently issuing "buy", "strong buy", and "conviction buy" ratings on.

#1 - Hyster-Yale Materials Handling (NYSE:HY)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$80.00 (34.4% Upside)

About Hyster-Yale Materials Handling

Hyster-Yale Materials Handling logoHyster-Yale Materials Handling, Inc, through its subsidiaries, designs, engineers, manufactures, sells, and services a line of lift trucks, attachments, and aftermarket parts worldwide. The company manufactures components, such as frames, masts, and transmissions; and assembles lift trucks. It markets its products primarily under the Hyster and Yale brand names to independent Hyster and Yale retail dealerships. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
12/5/2023Roth MkmInitiated CoverageBuy$85.00
11/15/2023Northland SecuritiesInitiated CoverageOutperform$80.00
3/1/2023EF Hutton Acquisition Co. IReiterated RatingBuy$75.00
10/12/2022SidotiUpgradeNeutral ➝ Buy$36.00


#2 - Kimbell Royalty Partners (NYSE:KRP)

Consensus Rating
Buy
Rating Score
3.1
Ratings Breakdown
7 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$21.00 (34.9% Upside)

About Kimbell Royalty Partners

Kimbell Royalty Partners logoKimbell Royalty Partners, LP, together with its subsidiaries, engages in acquiring and owning mineral and royalty interests in oil and natural gas properties in the United States. The company serves as the general partner of the company. Kimbell Royalty Partners, LP was incorporated in 2015 and is based in Fort Worth, Texas.
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
2/22/2024TD SecuritiesLower Price TargetBuy$26.00 ➝ $25.00
1/30/2024Truist FinancialInitiated CoverageBuy$22.00
1/24/2024Raymond JamesLower Price TargetStrong-Buy ➝ Strong-Buy$22.00 ➝ $20.00
1/11/2024KeyCorpLower Price TargetOverweight ➝ Overweight$21.00 ➝ $20.00
11/27/2023Stifel NicolausLower Price TargetBuy ➝ Buy$22.00 ➝ $21.00
10/30/2023Bank of AmericaInitiated CoverageBuy$19.00
8/25/2023Stifel NicolausBoost Price TargetBuy ➝ Buy$19.00 ➝ $22.00
8/7/2023Raymond JamesBoost Price TargetStrong-Buy ➝ Strong-Buy$20.00 ➝ $22.00
6/30/2023CitigroupReiterated RatingBuy ➝ Buy$20.00
4/14/2023Raymond JamesBoost Price TargetStrong-Buy$19.00 ➝ $21.00


#3 - Zura Bio (NASDAQ:ZURA)

Consensus Rating
Buy
Rating Score
3.2
Ratings Breakdown
5 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$16.60 (334.6% Upside)

About Zura Bio

Zura Bio logoZura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
10/10/2023LADENBURG THALM/SH SHInitiated CoverageBuy$10.00
8/24/2023OppenheimerInitiated CoverageOutperform$17.00
8/17/2023Chardan CapitalReiterated RatingBuy
8/15/2023Raymond JamesBoost Price TargetStrong-Buy ➝ Strong-Buy$20.00 ➝ $22.00
7/10/2023Chardan CapitalReiterated RatingBuy
6/22/2023GuggenheimInitiated CoverageBuy$20.00
6/14/2023Chardan CapitalInitiated CoverageBuy$14.00
5/24/2023Raymond JamesInitiated CoverageStrong-Buy$20.00


#4 - Teekay Tankers (NYSE:TNK)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$71.67 (29.9% Upside)

About Teekay Tankers

Teekay Tankers logoTeekay Tankers Ltd. provides marine transportation services to oil industries in Bermuda and internationally. The company offers voyage and time charter services; and offshore ship-to-ship transfer services of commodities primarily crude oil and refined oil products, as well as liquid gases and various other products. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
2/23/2024Evercore ISILower Price TargetOutperform ➝ Outperform$77.00 ➝ $73.00
2/22/2024Jefferies Financial GroupReiterated RatingBuy ➝ Buy$70.00
1/19/2024Bank of AmericaUpgradeNeutral ➝ Buy$56.00 ➝ $72.00
8/3/2023Jefferies Financial GroupBoost Price TargetBuy ➝ Buy$51.00 ➝ $54.00
2/23/2023Jefferies Financial GroupBoost Price TargetBuy$44.00 ➝ $51.00
11/29/2022Jefferies Financial GroupBoost Price TargetBuy$40.00 ➝ $44.00
11/3/2022Bank of AmericaUpgradeUnderperform ➝ Neutral
11/3/2022Jefferies Financial GroupBoost Price TargetBuy$35.00 ➝ $40.00
8/4/2022Jefferies Financial GroupBoost Price TargetBuy$25.00 ➝ $28.00
7/20/2022Jefferies Financial GroupInitiated CoverageBuy$25.00


#5 - V2X (NYSE:VVX)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
3 Buy Ratings, 1 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$58.00 (51.3% Upside)

About V2X

V2X logoV2X, Inc provides critical mission solutions and support services to defense clients in the United States and internationally. It offers a suite of integrated solutions across the operations and logistics, aerospace, training, and technology markets to national security, defense, and civilian clients. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
2/6/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$65.00
1/19/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$55.00
1/5/2024Stifel NicolausReiterated RatingBuy ➝ Hold$59.00 ➝ $52.00
11/13/2023JMP SecuritiesInitiated CoverageOutperform$65.00
11/7/2023Royal Bank of CanadaLower Price TargetOutperform ➝ Outperform$62.00 ➝ $55.00
11/7/2023Raymond JamesLower Price TargetStrong-Buy ➝ Strong-Buy$65.00 ➝ $60.00
8/9/2023Raymond JamesBoost Price TargetStrong-Buy ➝ Strong-Buy$60.00 ➝ $65.00
8/9/2023Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$60.00 ➝ $62.00
3/3/2023Raymond JamesBoost Price TargetStrong-Buy$50.00 ➝ $60.00
1/25/2023Royal Bank of CanadaInitiated CoverageOutperform$55.00


#6 - Adtalem Global Education (NYSE:ATGE)

Consensus Rating
Buy
Rating Score
3.0
Ratings Breakdown
3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$56.67 (15.0% Upside)

About Adtalem Global Education

Adtalem Global Education logoAdtalem Global Education Inc provides workforce solutions worldwide. It operates through three segments, Chamberlain, Walden, and Medical and Veterinary. The Chamberlain segment offers degree and non-degree programs in the nursing and health professions postsecondary education industry. This segment operates Chamberlain University. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
1/19/2024Barrington ResearchBoost Price TargetOutperform ➝ Outperform$55.00 ➝ $65.00
10/27/2023Barrington ResearchReiterated RatingOutperform ➝ Outperform$55.00
10/27/2023Robert W. BairdUpgradeNeutral ➝ Outperform$47.00 ➝ $55.00
9/14/2023Robert W. BairdReiterated RatingNeutral ➝ Neutral$47.00
8/14/2023BMO Capital MarketsBoost Price TargetOutperform ➝ Outperform$44.00 ➝ $50.00
8/11/2023Barrington ResearchBoost Price TargetOutperform ➝ Outperform$48.00 ➝ $55.00
7/7/2023BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$44.00
2/3/2023Barrington ResearchReiterated RatingOutperform$48.00
11/7/2022BMO Capital MarketsBoost Price TargetMarket Perform$44.00 ➝ $46.00
11/4/2022Barrington ResearchBoost Price Target$46.00 ➝ $48.00


#7 - Atlas Energy Solutions (NYSE:AESI)

Consensus Rating
Buy
Rating Score
3.1
Ratings Breakdown
10 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$24.90 (32.1% Upside)

About Atlas Energy Solutions

Atlas Energy Solutions logoAtlas Energy Solutions Inc provides proppant and logistics services to the oil and natural gas industry within the Permian Basin of West Texas and New Mexico. The company was founded in 2017 and is based in Austin, Texas.
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
2/28/2024Royal Bank of CanadaBoost Price TargetOutperform ➝ Outperform$23.00 ➝ $25.00
11/1/2023Raymond JamesLower Price TargetStrong-Buy ➝ Strong-Buy$27.00 ➝ $26.00
8/16/2023CitigroupBoost Price TargetBuy ➝ Buy$23.00 ➝ $26.00
8/3/2023The Goldman Sachs GroupBoost Price TargetBuy ➝ Buy$22.00 ➝ $24.00
8/2/2023Raymond JamesBoost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $27.00
8/2/2023Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$25.00
8/1/2023StephensReiterated RatingOverweight ➝ Overweight$23.00
4/12/2023Johnson RiceInitiated CoverageBuy$24.00
4/4/2023Capital One FinancialInitiated CoverageOverweight$25.00
4/3/2023Bank of AmericaInitiated CoverageBuy$23.00


#8 - North American Construction Group (NYSE:NOA)

Consensus Rating
Hold
Rating Score
2.3
Ratings Breakdown
1 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$39.00 (55.8% Upside)

About North American Construction Group

North American Construction Group logoNorth American Construction Group Ltd. provides equipment maintenance, and mining and heavy construction services in Canada, the United States, and Australia. Its Heavy Construction & Mining division offers constructability reviews, budgetary cost estimates, design-build construction, project management, contract mining, pre-stripping/pit pioneering, overburden removal and stockpile, muskeg removal and stockpile, site preparation, air strip construction, site dewatering/perimeter ditching, tailings and process pipelines, haulage and access road construction, tailings dam construction and densification, mechanically stabilized earth walls, dyke construction, and reclamation services; and Equipment Maintenance services. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
9/28/2023TD CowenReiterated RatingBuy ➝ Hold
9/28/2023TD SecuritiesDowngradeBuy ➝ Hold
7/28/2023Canaccord Genuity GroupBoost Price TargetBuy$30.00 ➝ $39.00
7/27/2023TD SecuritiesUpgradeHold ➝ Buy
2/17/2023National Bank FinancialBoost Price TargetC$27.00
2/17/2023TD SecuritiesDowngradeBuy ➝ Hold
2/16/2023BMO Capital MarketsBoost Price TargetC$24.00 ➝ C$25.00
10/27/2022BMO Capital MarketsBoost Price TargetC$20.00
8/1/2022Canaccord Genuity GroupLower Price TargetC$26.00 ➝ C$22.00
7/29/2022National Bank FinancialLower Price TargetC$20.00


#9 - InflaRx (NASDAQ:IFRX)

Consensus Rating
Buy
Rating Score
3.3
Ratings Breakdown
4 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$11.67 (548.1% Upside)

About InflaRx

InflaRx logoInflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
1/25/2024HC WainwrightLower Price TargetBuy ➝ Buy$9.00 ➝ $8.00
11/2/2023Raymond JamesLower Price TargetStrong-Buy ➝ Strong-Buy$21.00 ➝ $19.00
9/12/2023HC WainwrightReiterated RatingBuy ➝ Buy$9.00
8/31/2023HC WainwrightReiterated RatingBuy ➝ Buy$9.00
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$9.00
4/21/2023HC WainwrightLower Price TargetBuy$10.00 ➝ $9.00
4/5/2023Raymond JamesBoost Price TargetStrong-Buy$8.00 ➝ $25.00
4/5/2023GuggenheimUpgradeNeutral ➝ Buy$8.00
4/5/2023HC WainwrightBoost Price TargetBuy$6.00 ➝ $10.00
4/5/2023Lifesci CapitalUpgradeMarket Perform ➝ Outperform


#10 - Profound Medical (NASDAQ:PROF)

Consensus Rating
Moderate Buy
Rating Score
2.8
Ratings Breakdown
2 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$13.44 (49.3% Upside)

About Profound Medical

Profound Medical logoProfound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
1/4/2024Alliance Global PartnersLower Price TargetBuy ➝ Buy$14.25 ➝ $12.75
11/28/2023Stifel NicolausInitiated CoverageHold$11.00
9/18/2023Raymond JamesUpgradeOutperform ➝ Strong-Buy$20.00
8/4/2023Raymond JamesDowngradeStrong-Buy ➝ Outperform
6/5/2023Raymond JamesBoost Price TargetStrong-Buy$17.00 ➝ $20.00
3/21/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$5.50 ➝ $10.00
3/8/2023Raymond JamesBoost Price TargetStrong-Buy$15.00 ➝ $17.00
1/6/2023Lake Street CapitalBoost Price Target$7.00 ➝ $14.00
11/4/2022Alliance Global PartnersLower Price TargetBuy ➝ Buy$12.50 ➝ $6.50
11/4/2022Raymond JamesUpgradeOutperform ➝ Strong-Buy$15.00


More Investing Slideshows: